Biogen completed the acquisition of Alcyone Therapeutics for $85m.

Biogen, a global biotechnology company, completed the acquisition of Alcyone Therapeutics, a clinical-stage company focused on precision therapies and drug delivery systems, for $85m. “The ThecaFlex DRx™ allows us to merge Biogen’s cutting-edge biopharmaceutical innovation with advanced medical device technology to strengthen Biogen’s portfolio and expand our expertise in pioneering new delivery methods. This acquisition affirms our continued commitment to drug delivery solutions with the potential to enhance the patient experience and enable greater accessibility to Biogen’s therapies,” Lisa Shafer, Biogen Head of CMC Development, Product Delivery Solutions.